These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34637126)

  • 1. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.
    Trifirò G; Isgrò V; Ingrasciotta Y; Ientile V; L'Abbate L; Foti SS; Belleudi V; Poggi F; Fontana A; Moretti U; Lora R; Sabaini A; Senesi I; Sorrentino C; Puzo MR; Padula A; Fusco M; Giordana R; Solfrini V; Puccini A; Rossi P; Del Zotto S; Leoni O; Zanforlini M; Ancona D; Bavaro V; Garau D; Ledda S; Scondotto S; Allotta A; Tuccori M; Gini R; Bucaneve G; Franchini D; Cavazzana A; Biasi V; Spila Alegiani S; Massari M;
    BioDrugs; 2021 Nov; 35(6):749-764. PubMed ID: 34637126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project.
    Spini A; L'Abbate L; Ingrasciotta Y; Pellegrini G; Carollo M; Ientile V; Leoni O; Zanforlini M; Ancona D; Stella P; Cavazzana A; Scapin A; Lopes S; Belleudi V; Trifirò G
    Clin Epidemiol; 2024; 16():395-407. PubMed ID: 38854895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
    Pauline O; Robert M; Bernardeau C; Hlavaty A; Fusaroli M; Roustit M; Cracowski JL; Khouri C
    BioDrugs; 2023 Sep; 37(5):699-707. PubMed ID: 37278971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project.
    Ingrasciotta Y; Spini A; L'Abbate L; Fiore ES; Carollo M; Ientile V; Isgrò V; Cavazzana A; Biasi V; Rossi P; Ejlli L; Belleudi V; Poggi F; Sapigni E; Puccini A; Ancona D; Stella P; Pollina Addario S; Allotta A; Leoni O; Zanforlini M; Tuccori M; Gini R; Trifirò G
    Pharmacol Res; 2024 Feb; 200():107074. PubMed ID: 38232909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
    Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
    Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network.
    Spini A; Pellegrini G; Ingrasciotta Y; L'Abbate L; Bellitto C; Carollo M; Leoni O; Zanforlini M; Ancona D; Stella P; Cavazzana A; Scapin A; Lopes S; Belleudi V; Ledda S; Carta P; Rossi P; Ejlli L; Sapigni E; Puccini A; Spila Alegiani S; Massari M; Guarneri C; Gisondi P; Trifirò G
    Expert Opin Biol Ther; 2024 May; 24(5):399-409. PubMed ID: 38767132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 May; ():1-7. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy.
    Marcianò I; Randazzo MP; Panagia P; Intelisano R; Sgroi C; Ientile V; Cannavò S; Guarneri C; Reitano P; Spina E; Trifirò G
    G Ital Dermatol Venereol; 2020 Aug; 155(4):441-451. PubMed ID: 29582617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.
    Dormuth CR; Fisher A; Carney G
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):796-802. PubMed ID: 31914214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland.
    Duggan B; Smith A; Barry M
    Int J Clin Pharm; 2021 Oct; 43(5):1251-1256. PubMed ID: 33560486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.